In vivo transfection in avians
View Patent ↗The present invention provides for methods of producing transgenic avians which may include delivering a heterologous nucleic acid to oviduct tissue of an avian wherein the nucleic acid enters a cell of the oviduct tissue and is expressed.
1. A method of producing a transgenic avian comprising delivering a nucleic acid solution under pressure to oviduct tissue of an avian by injecting the nucleic acid solution into an artery selected from the group consisting of anterior oviductal artery, inferior uterine artery, superior uterine artery, and middle uterine artery, wherein the nucleic acid enters a cell of the oviduct tissue and is expressed, thereby producing a transgenic avian.
2. The method of claim 1 wherein the avian is selected from the group consisting of chicken, quail, turkey, duck, goose, pheasants, parrots, finches, hawks, crows, ratites, ostrich, emu and cassowary.
3. The meted of claim 1 wherein the avian is selected from the group consisting of chicken, quail and duck.
4. The method of claim 1 wherein the avian is a chicken.
5. The method of claim 1 wherein the pressure is hydrostatic pressure or hydrodynamic pressure.
6. The method of claim 1 wherein the cell is a tubular gland cell.
7. The method of claim 1 wherein the artery is occluded.
8. The method of claim 1 wherein the nucleic acid is DNA.
9. The method of claim 1 wherein the nucleic acid is a circular molecule.
10. The method of claim 1 wherein an expression construct comprises the nucleic acid.
11. The method of claim 1 wherein the nucleic acid comprises an attB site.
12. The method of claim 1 wherein DNA encoding integrase is delivered to the cell of the oviduct tissue.
13. The method of claim 1 wherein a polypeptide encoded by a coding sequence of the nucleic acid is present in egg white produced by the transgenic avian.
14. The method of claim 13 wherein the polypeptide is a pharmaceutical.
15. The method of claim 14 wherein the pharmaceutical is a light chain or a heavy chain of an antibody.
16. The method of claim 15 wherein the antibody is a human antibody.
17. The method of claim 14 wherein the pharmaceutical is a cytokine.
18. The method of claim 14 wherein the pharmaceutical is selected from the group consisting of erythropoietin and interferon.
19. A method of producing a transgenic avian comprising delivering a nucleic acid solution under hydrostatic pressure to oviduct tissue of an avian by injecting the nucleic acid solution into an artery selected from the group consisting of anterior oviductal artery, inferior uterine artery, superior uterine artery, and middle uterine artery, wherein the nucleic acid enters a cell of the oviduct tissue and is expressed, thereby producing a transgenic avian.
20. The method of claim 19 wherein the avian is selected from the group consisting of chicken, quail, turkey, duck, goose, pheasants, parrots, finches, hawks, crows, ratites, ostrich, emu and cassowary.
21. The method of claim 19 wherein the avian is selected from the group consisting of chicken, quail and duck.
22. The method of claim 19 wherein the avian is a chicken.
23. The method of claim 19 wherein the nucleic acid comprises an attB site.
24. The method of claim 19 wherein DNA encoding integrase is delivered to the cell of the oviduct tissue.
25. The method of claim 19 wherein the cell is a tubular gland cell.
26. The method of claim 19 wherein the nucleic acid is a vector.
27. The method of claim 19 wherein an expression construct comprises the nucleic acid.
28. The method of claim 19 wherein a polypeptide encoded by a coding sequence of the nucleic acid is present in egg white produced by the transgenic avian.
29. The method of claim 28 wherein the polypeptide is a pharmaceutical.
30. The method of claim 29 wherein the pharmaceutical is a light chain or a heavy chain of an antibody.
31. The method of claim 29 wherein the pharmaceutical is a cytokine.
32. The method of claim 19 wherein the artery is occluded.